文章预览
SCI 26 April 2025 HER2 testing: evolution and update for a companion diagnostic assay (Nature Reviews Clinical Oncology, IF: 81.1) Charles J. Robbins, Katherine M. Bates & David L. Rimm CORRESPONDENCE TO: david.rimm@yale.edu Abstract 摘要 空白 Human epidermal growth factor receptor 2 (HER2; encoded by ERBB2) testing has been a cornerstone of patient selection for HER2-targeted therapies, principally in breast cancer but also in several other solid tumours. Since the introduction of Hercep Test as the original companion diagnostic for trastuzumab, HER2 assessment methods have evolved substantially, incorporating various testing modalities, from western blots, immunohistochemistry and fluorescence in situ hybridization, to early chromogenic quantitative methods and, probably in the future, fully quantitative methods. The advent of highly effective HER2-targeted antibody–drug conjugates with clinical activity at low levels of HER2 expression, such as trastuzumab deruxtecan, ha
………………………………
